Lineage Cell Therapeutics (LCTX) Operating Income (2010 - 2026)

Lineage Cell Therapeutics' Operating Income history runs 17 years deep, the most recent figure standing at -$7.6 million for Q1 2026.

• On a quarterly basis, Operating Income fell 16.73% year-over-year to -$7.6 million in Q1 2026; TTM through Mar 2026 was -$37.7 million, a 76.85% decrease from a year earlier, with the FY2025 full-year figure at -$36.6 million, down 70.5% from the prior year.
• Operating Income retreated to -$7.6 million in Q1 2026 per LCTX's latest filing, from -$6.5 million in the prior quarter.
• Across five years, Operating Income topped out at -$3.8 million in Q3 2025 and bottomed at -$19.8 million in Q2 2025.
• The 5-year median for Operating Income is -$6.4 million (2022), against an average of -$6.6 million.
• Across the five-year window, Operating Income jumped 76.49% in 2022 and sank 237.14% in 2025, its largest moves.
• Year by year, Operating Income stood at -$6.6 million in 2022, then rose by 4.17% to -$6.4 million in 2023, then grew by 19.68% to -$5.1 million in 2024, then declined by 28.14% to -$6.5 million in 2025, then dropped by 15.96% to -$7.6 million in 2026.
• Per Business Quant, the three latest LCTX Operating Income figures stand at -$7.6 million (Q1 2026), -$6.5 million (Q4 2025), and -$3.8 million (Q3 2025).